Celgene Corporation (NASDAQ:CELG) today announced results from an
international phase III study of REVLIMID® (lenalidomide) compared with
placebo in patients with red-blood cell (RBC) transfusion dependent
low-risk myelodysplastic syndromes (MDS) who were unresponsive or
refractory to erythropoietin stimulating agents (ESA) and did not have a
deletion 5q cytogenic abnormality.
for Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH investment picks